Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT02087943

Public ClinicalTrials.gov record NCT02087943. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis

Study identification

NCT ID
NCT02087943
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
191 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2014 (Type not available)
Primary completion
Oct 2015 (Actual)
Completion
Feb 2016 (Actual)
Last update posted
May 7, 2020

2014 – 2016

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Arizona Research Center Phoenix Arizona 85023 —
Bakersfield Dermatology and Skin Cancer Medical Group Bakersfield California 93309 —
Dermatology Research Associates Los Angeles California 90045 —
Renstar Medical Research Ocala Florida 34471 —
Emory Clinic Atlanta Georgia 30322 —
Advanced Medical Research Atlanta Georgia 30342 —
Northwestern University Northwestern Medical Faculty Foundation Chicago Illinois 60611 —
Northwestern Medicine Lake Forest Hospital Lake Forest Illinois 60045 —
Dermatology Specialists, PSC Louisville Kentucky 40202 —
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756 —
NYU Department of Dermatology New York New York 10016 —
Mount Sinai Medical Center New York New York 10029 —
PMG Research of Winston-Salem LLC Winston-Salem North Carolina 27103-3914 —
Oregon Health and Science University Portland Oregon 97201-3098 —
Virginia Clinical Research Inc Norfolk Virginia 23507 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02087943, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2020 · Synced Oct 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02087943 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →